Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects.

What Was Tested

This randomized controlled trial looks at Indomethacin and Enalapril.

The purpose of the present study was to investigate the acute and sustained effects of indomethacin on the renal response to the angiotensin II receptor antagonist valsartan and to the ACE inhibitor enalapril.

Why It Was Studied

Non-steroidal anti-inflammatory drugs are known to promote sodium retention and to blunt the blood pressure lowering effects of several classes of antihypertensive agents including beta-blockers, diuretics and angiotensin converting enzyme (ACE) inhibitors.

Who Took Part

The age groups tagged for this paper are adults, men only.

How the Study Was Run

In design terms this was a randomized, single-blind, crossover and parallel-group study.

Because people in this Indomethacin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Only one side, usually the participants, was kept unaware of whether Indomethacin was given.

In the crossover set-up each of the participants took both Indomethacin and the comparison in turn, acting as their own control.

The Indomethacin group and the comparison group ran side by side rather than switching.

This single-blind study was designed as a parallel (valsartan vs. enalapril) and cross-over trial (valsartan or enalapril vs. valsartan + indomethacin or enalapril + indomethacin).

What Was Measured

Topics PubMed links to this paper include Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Anti-Inflammatory Agents, Non-Steroidal, Enalapril, Indomethacin, Kidney and Natriuresis.

What This Means in Plain Language

The paper is a randomized, single-blind and crossover study of Indomethacin and Enalapril.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1998 (Kidney international), a journal based in United States.

More context: all human trials.